Primary pulmonary hypertension

Lancet

Volumn 352, Issue 9129, 1998, Pages 719-725

  Gaine, Sean P ^a   Rubin, Lewis J ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; PROSTACYCLIN; VASODILATOR AGENT;

ENDOTHELIUM CELL; EXERCISE TOLERANCE; FAMILIAL DISEASE; FEMALE; GENETIC PREDISPOSITION; HEART AFTERLOAD; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG HEMODYNAMICS; LUNG VASCULAR RESISTANCE; PATHOGENESIS; PRIORITY JOURNAL; PULMONARY ARTERY; PULMONARY HYPERTENSION; REVIEW; SMOOTH MUSCLE FIBER; SURVIVAL;

EID: 0032578279     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(98)02111-4     Document Type: Review

References (39)

1. Romberg E. Lieber sklerose der Lungen arterie. Dtsch Archiv Klin Med 1891; 48: 197-206.
2. Dresdale DT, Schultz M, M ich torn RJ. Primary pulmonary hypertension: clinical and haemodynamic study. Am J Med 1951; 11: 686-705.
3. Connolly H , Crary J, McGoon M , et al. Valvular heart disease associated with fen fluramine-phentermine. N EngtJ Med 1997; 337: 581-88.
4. Rubin L. ACCP consensus statement: primary pulmonary hypertension. Chest 1987; 104: 236-50.
5. Wood P. Pulmonary hypertension with special reference to the vasoconstrictive factor. Br Heart J 1958; 2: 557-70.
6. McDonnell P, Toye P, Hutchins G. Primary pulmonary hypertension and cirrhosis: are they related? Am Rev Respir Dis 1983; 127: 437-41.
7. Abenhaim L, Moride Y, Brenot F, et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension: International Primary Pulmonary Hypertension study group. N EngtJ Med 1996; 335: 609-16.
8. Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension: a national prospective study. Ann Intern Med 1987; 107: 216-23.
9. Loyd JE, Butler MG, Foround TM, et al. Genetic anticipation and abnormal gender ratio at birth in familial primary pulmonary hypertension. Am J Respir Crit Care Med 1995; 152: 93-97.
10. Loyd J, RK, Newman J. Familial primary pulmonary hypertension: clinical patterns. Am Rev Respir Dis 1984; 129: 194-97.
11. Hatano S, Strasser T. Primary pulmonary hypertension. Geneva: WHO, 1975: 1-46.
12. Heath D, Edwards JE. The pathology of hypertensive pulmonary vascular disease: a description of six grades of structural changes in the pulmonary arteries with special reference to congenital cardiac septal defects. Circulation 1958; 18: 533-47.
13. Palevsky HI, Schloo BL, Pietra GG. Primary pulmonary hypertension: vascular structure, morphometry and responsiveness to vasodilator agents. Circulation 1989; 80: 1207-21.
14. Pietra GG, Edwards WD, Kay JM , et al. Histopathology of pulmonary hypertension: a qualitative and quantitative study of pulmonary blood vessels from 58 patients in National Heart, Lung, and Blood Institute Primary Pulmonary Hypertension Registry. Circulation 1989; 80: 1198-206.
15. Nichols W, Koller D, Slovis B, et al. Localization of the gene for familial primary pulmonary hypertension to chromosome 2q31-32. Nat Genet 1997; 15: 277-80.
16. Wagenvoort C, Wagenvoort N. Primary pulmonary hypertension: a pathological study ofthe lung vessels in 156 clinically diagnosed cases. Circulation 1970; 42: 1163-84.
17. Giaid A, Saleh D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N N EngtJ Medi/1995; 333: 214-21.
18. Giaid A, Yanagisawa M, Langleben D, et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 1993;328:1732-39.
19. Herve P, Launay JM, Scrobohaci ML, et al. Increased plasma serotonin in primary pulmonary hypertension. Am J Med 1995; 99: 249-54.
20. + channel gene transcription in primary pulmonary hypertension. Lancet 1998; 352: 726-27.
21. Voelkel N, Tuder R, Weir E. Pat hop hysio logy of primary pulmonary hypertension: from physiology to molecular mechanisms. In: Rubin L, Rich S, eds. Primary pulmonary hypertension. New York: Marcel Dekker, 1997: 83-130.
22. Hinderliter AL, Willis PW, Barst RJ, et al. Effects of long-term infusion of prostacyclin (epoprostenol) on echocardiographic measures of right ventricular structure and function in primary pulmonary hypertension: Primary Pulmonary Hypertension study group. Circulation 1997; 95: 1479-86.
23. D'Alonzo G, Gianotti LA, Pohil RL, et al. Comparison of progressive exercise performance of normal subjects and patients with primary pulmonary hypertension. Chest 1987; 92: 57-62.
24. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension: the Primary Pulmonary Hypertension study group. N Engl J M ed 1996; 334: 296-302.
25. Kessler R, Chaouat A, Weitzenblum E, et al. Pulmonary hypertension in the obstructive sleep apnea syndrome: prevalence, causes and therapeutic consequences. EurRespir J 1996; 9: 787-94.
26. D'Alonzo G, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension: results from a national prospective registry. Ann Intern Med 1991; 115: 3439.
27. Pepke-Zaba J, Higenbottam TW, Dinh-Xuan AT, Stone D, Wallwork J. Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension. Lancet 1991 ; 338: 1173-74.
28. Rubin L, Groves B, Reeves J, et al. Prostacyclin-indiced acute pulmonary vasodilation in primary pulmonary hypertension. Circulation 1982; 66: 334-38.
29. Oakley C, Sommerville J. Oral contraceptives and progressive pulmonary vascular disease. Lancet 1968; i: 890-91.
30. Weir E, Rubin L, Ayres S, et al. The acute administration of vasodilators in primary pulmonary hypertension: experience from the National Institutes of Health Registry on primary pulmonary hypertension. Am Rev RespirDis 1989; 140: 1623-30.
31. H igen bot tarn T, Wells F, Wheeldon D, Wallwork J. Long-term treatment of primary pulmonary hypertension with continuous intravenous epoprostenol (prostacyclin). Lancet 1984; i: 1046-47.
32. Rubin LJ, Mendoza J, Hood M, et al. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol): results ofa randomized trial. Ann Intern Med 1990; 112: 485-91.
33. Fuster V, SteelePM, Edwards WD. Gersh BJ, McGoon MD, Frye RL. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation 1984; 70: 580-87.
34. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N EnglJ Med 1992; 327: 76-81.
35. Higenbottam TW, Spiegelhalter D, Scott JP, et al. Prostacyclin (epoprostenol) and heart-lung transplantation as treatments for severe pulmonary hypertension. Br Heart J 1993; 70: 366-70.
36. Pasque MK, Kaiser LR, Dresler CM, TrulockE, Triantafillou AN, Cooper JD. Single lung transplantation for pulmonary hypertension: technical aspects and immediate hemodynamic results. J Thorac CardiovascSurg 1992; 103: 475-81.
37. Oakley C. Primary pulmonary hypertension: case series from the United Kingdom. Chest 1994; 105 (suppl): 29S-32S.
38. Brenot F. Primary pulmonary hypertension: case series from France. Chest 1994; 105 (suppl): 33S-36S.
39. Gaine S, Rubin L. Medical and surgical treatment options for pulmonary hypertension. Am J Med Sci 1998; 315: 179-84.